FDA Approves
The Pharma Data
JUNE 2, 2023
Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. 0.45]) and overall survival (OS) (HR=0.30 [95% CI, 0.15-0.59]) Based on exploratory analyses of rPFS and OS in the BRCA m and non- BRCA m subgroups (non- BRCA subgroup rPFS HR=0.77 [95% CI, 0.63-0.96]; In the U.S.,
Let's personalize your content